Blinatumomab/BlincytoTM (also known as AMG103 or MT103) is an anti-CD19 × CD3 BiTE developed and licensed by Amgen for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (R/R ALL) treatment (Figure 1). Here, CD19 is linked to acute lymphoblastic leukemia.